Nitronazine by Guangzhou Magpie Pharmaceutical for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Amyotrophic Lateral Sclerosis.

FDA Approves First Drug for Classic Congenital Adrenal Hyperplasia in 70 Years

The FDA approved crinecerfont (Crenessity) as a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), the agency announced late Friday. Crinecerfont was approved for use

December 17, 2024

A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived

A U.S. appeals court revived a controversial lawsuit brought by nearly two dozen people who claimed they were harmed by a contaminated rare disease medicine

February 20, 2024

American Heart Association’s merit award recipients announced

The AHA celebrates 100 years of lifesaving work by announcing the recipients of its prestigious Merit Award.

January 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.